Advanced search
Publication Cover
Therapeutic Delivery Volume 2, 2011 - Issue 3
Submit an article Journal homepage
117
Views
1
CrossRef citations to date
0
Altmetric
Review

Individualizing Therapy of Monoclonal Antibodies and Fusion Proteins: Emerging Potential in the Age of Personalized Medicine

Christian Grimstein1 Office of Clinical Pharmacology Center for Drug Evaluation & Research US FDA10903 New Hampshire AvenueSilver SpringMD20993USA;2 [email protected]
&
Jane PF Bai1 Office of Clinical Pharmacology Center for Drug Evaluation & Research US FDA10903 New Hampshire AvenueSilver SpringMD20993USA
Pages 369-381 | Published online: 09 Mar 2011

Bibliography

  • Menard S , PupaSM, CampiglioM, TagliabueE. Biologic and therapeutic role of HER2 in cancer. Oncogene22(42), 6570–6578 (2003).
  • Vogel CL , CobleighMA, TripathyDet al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719–726 (2002).
  • Clynes RA , TowersTL, PrestaLG, RavetchJV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6(4), 443–446 (2000).
  • Carson W e, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to herceptin-coated HER2/neu-positive breast cancer cells. Eur. J. Immunol.31(10), 3016–3025 (2001).
  • Gennari R , MenardS, FagnoniFet al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10(17), 5650–5655 (2004).
  • Arnould L , GellyM, Penault-LlorcaFet al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2), 259–267 (2006).
  • Robertson M j, Ritz J. Biology and clinical relevance of human natural killer cells. Blood76(12), 2421–2438 (1990).
  • Koene H r, Kleijer M, Algra J, Roos D, Von Dem Borne Ae, De Haas M.FcγRIIIA-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa–48L/R/H phenotype. Blood90(3), 1109–1114 (1997).
  • Shields RL , NamenukAK, HongKet al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRN and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276(9), 6591–6604 (2001).
  • Warmerdam PA , Van De Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J. Immunol.147(4), 1338–1343 (1991).
  • Varchetta S , GibelliN, OlivieroBet al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res. 67(24), 11991–11999 (2007).
  • Musolino A , NaldiN, BortesiBet al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789–1796 (2008).
  • Lejeune J , ThibaultG, TernantD, CartronG, WatierH, OhresserM. Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in white patients, and for an FcγrRIIIa-restricted influence on the response to therapeutic antibodies. J. Clin. Oncol.26(33), 5489–5491 (2008); Author reply 5491–5482 (2008).
  • Ternant D , OhresserM, ThomasC, CartronG, WatierH, PaintaudG. Dose–response relationship and pharmacogenetics of anti-rhd monoclonal antibodies. Blood106(4), 1503–1504 (2005); Author reply 1504–1505 (2005).
  • Manches O , LuiG, ChaperotLet al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood101(3), 949–954 (2003).
  • Golay J , ZaffaroniL, VaccariTet al. Biologic response of b lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12), 3900–3908 (2000).
  • Winter MC , HancockBW. Ten years of rituximab in NHL. Expert Opin Drug Saf8(2), 223–235 (2009).
  • Cartron G , DacheuxL, SallesGet al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99(3), 754–758 (2002).
  • Weng WK , LevyR. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21(21), 3940–3947 (2003).
  • Paiva M , MarquesH, MartinsA, FerreiraP, CatarinoR, MedeirosR. FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet. Cytogenet.183(1), 35–40 (2008).
  • Kim DH , JungHD, KimJGet al. FCGR3a gene polymorphisms may correlate with response to frontline r-CHOP therapy for diffuse large B-cell lymphoma. Blood108(8), 2720–2725 (2006).
  • Weng WK , LevyR. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk. Lymphoma50(9), 1494–1500 (2009).
  • Ferlay J , Shin Hr, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int. J. Cancer DOI: 10.1002/ijc.25516 (2010) (Epub ahead of print).
  • Saltz LB , Meropol Nj, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
  • Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337–345 (2004).
  • Hecht JR , PatnaikA, BerlinJet al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5), 980–988 (2007).
  • Berlin J , PoseyJ, TchekmedyianSet al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 6(6), 427–432 (2007).
  • Chung KY , ShiaJ, KemenyNEet al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803–1810 (2005).
  • Benvenuti S , Sartore-BianchiA, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res.67(6), 2643–2648 (2007).
  • Lievre A , BachetJB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
  • Lievre A , BachetJB, BoigeVet al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374–379 (2008).
  • Karapetis CS , Khambata-FordS, JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
  • Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626–1634 (2008).
  • Bokemeyer C , BondarenkoI, MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663–671 (2009).
  • Linardou H , Dahabreh Ij, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol.9(10), 962–972 (2008).
  • Di Nicolantonio F , MartiniM, MolinariFet al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705–5712 (2008).
  • Rajagopalan H , BardelliA, LengauerC, KinzlerKW, VogelsteinB, VelculescuVE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.Nature418(6901), 934 (2002).
  • Sartore-Bianchi A , MoroniM, VeroneseSet al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25(22), 3238–3245 (2007).
  • Cappuzzo F , FinocchiaroG, RossiEet al. EGFR fish assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19(4), 717–723 (2008).
  • Khambata-Ford S , GarrettCR, MeropolNJet al. Expression of epiregulin and amphiregulin and k-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230–3237 (2007).
  • Frattini M , SalettiP, RomagnaniEet al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer. 97(8), 1139–1145 (2007).
  • Sartore-Bianchi A , MartiniM, MolinariFet al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res.69(5), 1851–1857 (2009).
  • Prenen H , De Schutter J, Jacobs B et al.PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res.15(9), 3184–3188 (2009).
  • Shahbazi M , FryerAA, PravicaVet al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13(1), 260–264 (2002).
  • Schneider BP , WangM, RadovichMet al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672–4678 (2008).
  • Mugnier B , NathalieB, AlbertD, ChantalR, JeanR, DenisR. Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum.48(7), 1849–1852 (2003).
  • Fonseca JE , CarvalhoT, CruzMet al. Polymorphism at position -308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics. Ann. Rheum. Dis. 64(5), 793–794 (2005).
  • Cuchacovich M , SotoL, EdwardesMet al. Tumour necrosis factor (TNF)α -308 G/G promoter polymorphism and TNF-α levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35(6), 435–440 (2006).
  • Seitz M , WirthmullerU, MollerB, VilligerPM. The -308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNF-α-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford)46(1), 93–96 (2007).
  • Guis S , NathalieB, JulienBet al. Influence of -308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis. Arthritis Care Research 57(8), 1426–1430 (2007).
  • Maxwell JR , PotterC, HyrichKLet al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum. Mol. Genet. 17(22), 3532–3538 (2008).
  • Cuchacovich M , FerreiraL, AlisteMet al. Tumour necrosis factor-α (TNF-α) levels and influence of -308 TNF-α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand. J. Rheumatol. 33(4), 228–232 (2004).
  • Marotte H , BéatriceA, JenniferD, SalouaZ, PierreM. Association between the level of circulating bioactive tumor necrosis factor and the tumor necrosis factor α gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor. Arthritis Rheum.58(5), 1258–1263 (2008).
  • Lee YH , JiJD, BaeSC, SongGG. Associations between tumor necrosis factor-α (TNF-α) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-α blockers in rheumatoid arthritis: a meta-analysis update. J. Rheumatol.37(4), 740–746 (2010).
  • Pavy S , Toonen Ej, Miceli-Richard C et al. Tumour necrosis factor α -308G->A polymorphism is not associated with response to TNF-α blockers in caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis.69(6), 1022–1028 (2010).
  • Miceli-Richard C , CometsE, VerstuyftCet al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann. Rheum. Dis. 67(4), 478–484 (2008).
  • Padyukov L , LampaJ, HeimburgerMet al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62(6), 526–529 (2003).
  • Tutuncu Z , KavanaughA, ZvaiflerN, CorrM, DeutschR, BoyleD: Fcγ receptor type IIIa polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents.Arthritis Rheum.52(9), 2693–2696 (2005).
  • Canete JD , SuarezB, HernandezMVet al. Influence of variants of Fcγ receptors IIa and IIIa on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor α therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68(10), 1547–1552 (2009).
  • Kastbom A , BrattJ, ErnestamSet al. Fcγ receptor type IIIa genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56(2), 448–452 (2007).
  • Rooryck C , BarnetcheT, RichezC, LaleyeA, ArveilerB, SchaeverbekeT: Influence of FCGR3a-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy.Clin. Exp. Rheumatol.26(2), 340–342 (2008).
  • Toonen EJ , CoenenMJ, KievitWet al. The tumour necrosis factor receptor superfamily member 1B 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 67(8), 1174–1177 (2008).
  • Criswell LA , LumRF, TurnerKNet al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50(9), 2750–2756 (2004).
  • Holbro T , HynesNE. ERBB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol.44, 195–217 (2004).
  • Klapper LN , KirschbaumMH, SelaM, YardenY. Biochemical and clinical implications of the ERBB/HER signaling network of growth factor receptors. Adv. Cancer Res.77, 25–79 (2000).
  • Madson JG , HansenLA. Multiple mechanisms of ERBB2 action after ultraviolet irradiation of the skin. Mol. Carcinog.46(8), 624–628 (2007).
  • Lenz HJ . Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology20(5 Suppl. 2), 5–13 (2006).
  • Gordon LI , BurkeMA, SinghATet al. Blockade of the ERBB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J. Biol. Chem. 284(4), 2080–2087 (2009).
  • Ewer SM , EwerMS. Cardiotoxicity profile of trastuzumab. Drug Saf.31(6), 459–467 (2008).
  • Zachary I , GlikiG. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res.49(3), 568–581 (2001).
  • Sung HK , MichaelIP, NagyA. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr. Opin. Hematol.17(3), 206–212 (2010).
  • Cebe Suarez S , PierenM, CariolatoLet al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 63(17), 2067–2077 (2006).
  • Advani A , Kelly Dj, Advani Sl et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc. Natl Acad. Sci. USA104(36), 14448–14453 (2007).
  • Schrijvers BF , FlyvbjergA, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int.65(6), 2003–2017 (2004).
  • Kuenen BC , LeviM, MeijersJCet al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22(9), 1500–1505 (2002).
  • Rodriguez-Porcel M , CaiW, GheysensOet al. Imaging of VEGF receptor in a rat myocardial infarction model using pet. J. Nucl. Med. 49(4), 667–673 (2008).
  • Hagikura K , FukudaN, YokoyamaSet al. Low invasive angiogenic therapy for myocardial infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene. Int. J. Cardiol. 142(1), 56–64 (2010).
  • Chung ES , PackerM, LoKH, FasanmadeAA, WillersonJT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (attach) trial. Circulation107(25), 3133–3140 (2003).
  • Mann D l, Mcmurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation109(13), 1594–1602 (2004).
  • Listing J , StrangfeldA, KekowJet al. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 58(3), 667–677 (2008).
  • Mann D l, Bozkurt B, Torre-Amione G, Soran Oz, Sivasubramanian N. Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin. Transl. Sci.1(2), 142–145 (2008).
  • Dedeoglu F : Drug-induced autoimmunity.Curr. Opin. Rheumatol.21(5), 547–551 (2009).
  • Stubenrauch K , WesselsU, BirnboeckH, RamirezF, JahreisA, SchleypenJ. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin. Ther.32(9), 1597–1609 (2010).
  • De Caterina R , ZimarinoM. Understanding the complexity of abciximab-related thrombocytopenia. Thromb. Haemost.103(3), 484–486 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.